BioNotebook: Pharmacyclics rises on Imbruvica sales; Allergan eye pact; Progenics, Cytokinetics, Nuvilex raise cash
This article was originally published in Scrip
The first glimpse of sales for the Pharmacyclics lymphoma and leukemia drug Imbruvica (ibrutinib) sent the Sunnyvale, California-based company's stock up 6.3% for a new high of $151.61 per share on 21 February.
You may also be interested in...
IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.